Peer-Reviewed Journal Details
Mandatory Fields
Flynn J.;Ryan A.;Hudson S.P.
2022
February
European Journal Of Pharmaceutics And Biopharmaceutics
Synergistic antimicrobial interactions of nisin A with biopolymers and solubilising agents for oral drug delivery
Published
3 ()
Optional Fields
Antimicrobial Synergy Antimicrobial Therapeutics Bacteriocins Biotechnology Drug Development Pre Formulation
171
29
38
In order to develop bacteriocins, like the lantibiotic nisin A, into effective alternatives to existing antibiotics, their biophysical and physicochemical properties must first be assessed, from solubility, to susceptibility and absorption. It has been well established that formulation strategies at early drug development stages can be crucial for successful outcomes during preclinical and clinical phases of development, particularly for molecules with challenging physicochemical properties. This work elucidates the physicochemical challenges of nisin A in terms of its susceptibility to digestive enzymes like pepsin, pancreatin and proteinase K and its poor solubility at physiological pHs. Low solution concentrations, below the minimum inhibitory concentration against Staphylococcus aureus, were obtained in phosphate buffered saline (PBS, pH 7.4) and in fasted state simulated intestinal fluid (FaSSIF, pH 6.5), while higher solubilities at more acidic pH's such as in a KCl/HCl buffer (pH 2) and in fasted state simulated gastric fluid (FaSSGF, pH 1.6) are observed. Tween® 80 (0.01% v/v) significantly increased the solution concentration of nisin A in PBS (pH 7.4, 24 hr). Pancreatin doubled nisin A's solution concentration at pH 7.4 (PBS) but reduced its¿ inhibitory activity to ~ 20%, and pepsin almost completely degraded nisin (after 24 hr), but retained activity at biologically relevant exposure times (~15 min). Harnessing synergism between nisin A and either glycol chitosan or ¿-poly lysine, combined with the solubilizing effect of Tween®, increased the antimicrobial activity of nisin A six fold in an in vitro oral administration model.
0939-6411
10.1016/j.ejpb.2021.12.010
Grant Details